Cogent Biosciences (COGT) Debt Ratio (2025)
Cogent Biosciences (COGT) posted quarterly Debt Ratio of 0.1 for Q3 2025, down 35.04% quarter-over-quarter from 0.16 in Q2 2025.
Powered by 
Analysis
Cogent Biosciences (COGT) Debt Ratio (2025) Analysis & Trends
Cogent Biosciences (COGT) has reported Debt Ratio for 1 consecutive years, with 0.1 the latest figure, recorded in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.05 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.47 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.26 |
| 10 | Cogent Biosciences | 5.94 Bn | 5.94 Bn | - | - |